Background
Tumor
NASOPHARYNGEAL CARCINOMA, TUMOR
Edited by: Xinqi Huang, Sichuan University, ChinaReviewed by: Jiaxiang Ye, Affiliated Tumor Hospital of Guangxi Medical University, ChinaDa Zhang, Benitec Biopharma, Inc., United StatesMinghan Yang, New York University, United StatesKai Song, University of California, Los Angeles, United StatesXin Xu, Kansas State University, United StatesShanshan Lin, Johns Hopkins University, United StatesDandan Mao, University of Massachusetts Medical School, United States†These authors contributed equally to this work and share first authorshipPreclinical studies demonstrated that immune checkpoint inhibitors combined with antiangiogenic drugs have a synergistic anti-tumor effect. This present phase II trial aimed to evaluate the efficacy and safety of apatinib combined with camrelizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).